Are New Omicron Subvariants a Threat? How Scientists are Keeping Watch
In South Africa, a network of researchers are studying whether new lineages BA.4 and BA.5 escape immunity from COVID-19 vaccines and prior infections
Amy Maxmen is a senior reporter at Nature based in Oakland California. Follow Amy Maxmen on Twitter @amymaxmen
In South Africa, a network of researchers are studying whether new lineages BA.4 and BA.5 escape immunity from COVID-19 vaccines and prior infections
The reports’ authors say that the novel coronavirus, or SARS-CoV-2, jumped from animals sold at the market to people twice in late 2019—but some scientists want more definitive evidence...
Celebrated sociologist Alondra Nelson and genome leader Francis Collins will temporarily split Lander’s duties
Studies suggest that a reversal of the landmark Roe v. Wade decision would be detrimental for many
The WHO-approved RTS,S vaccine has a modest efficacy and requires a complex regimen of doses, so ample funding and clear communication are crucial to success
An examination of the arguments that SARS-CoV-2 escaped from a lab in China and the science behind them
Allegations that COVID escaped from a Chinese lab make it harder for nations to collaborate on ending the pandemic—and fuel online bullying—some scientists say
In California’s San Joaquin Valley, some researchers are turning political to address the social determinants of health
The development from the Biden administration draws cheers from public health researchers and ire from drugmakers
Scientists say the conclusions make sense but note that supporters of the lab-leak theory are unlikely to be satisfied
Biden health official Rachel Levine has a strong track record of fighting for social justice in health care, researchers say
Open repository will give free access to more than 160 million data points with details about individual infections
The coronavirus pandemic, climate change and space exploration are among the issues that Biden will influence if he wins the upcoming U.S. election
Political meddling, disorganization and years of neglect of public-health data management mean the country is flying blind
The scenarios foresaw leaky travel bans, a scramble for vaccines and disputes between state and federal leaders, but none could anticipate the current levels of dysfunction in the U.S.
The epidemic killed more than 2,000 people—but involved the first widespread use of a vaccine against the virus
As President Trump terminates the U.S.’s relationship with the agency, experts foresee incoherence, inefficiency and a resurgence of deadly diseases
An online survey reveals bottlenecks, challenges and barriers faced by more than 1,700 biology labs
The lack of a national strategy has stymied the efforts of academic labs that underwent huge efforts to retool for COVID-19 testing
New York City researchers hope antibody-rich plasma can keep people out of intensive care
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account